Literature DB >> 11085980

Regulation of urokinase/urokinase receptor interaction by heparin-like glycosaminoglycans.

M Pucci1, G Fibbi, L Magnelli, M Del Rosso.   

Abstract

We show here that the interaction between the urokinase-type plasminogen activator and its receptor, which plays a critical role in cell invasion, is regulated by heparan sulfate present on the cell surface and in the extracellular matrix. Heparan sulfate oligomers showing a composition close to the dimeric repeats of heparin (glucosamine-NSO(3)(6-OSO(3))-iduronic acid(2-OSO(3))) n = 5 and n > 5, where iduronic acid may alternate with glucuronic acid, exhibit affinity for urokinase plasminogen activator and confer specificity on urokinase/urokinase receptor interaction. Cell surface clearance of heparan sulfate reduces the affinity of such interaction with a parallel decrease of specific urokinase binding in the presence of an unaltered expression of receptor. Transfection of human urokinase plasminogen activator receptor in normal Chinese hamster ovary fibroblasts and in Chinese hamster ovary cells defective for the synthesis of sulfated glycosaminoglycans results in specific urokinase/receptor interaction only in nondefective cells. Heparan sulfate/urokinase and receptor/urokinase interactions exhibit similar K(d) values. We concluded that heparan sulfate functions as an adaptor molecule that confers specificity on urokinase/receptor binding.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11085980     DOI: 10.1074/jbc.M005993200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Heparan sulfate proteoglycans mediate factor XIIa binding to the cell surface.

Authors:  Lukasz Wujak; Miroslava Didiasova; Dariusz Zakrzewicz; Helena Frey; Liliana Schaefer; Malgorzata Wygrecka
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

2.  Cross-talk of anosmin-1, the protein implicated in X-linked Kallmann's syndrome, with heparan sulphate and urokinase-type plasminogen activator.

Authors:  Youli Hu; David González-Martínez; Soo-Hyun Kim; Pierre Marc Gilles Bouloux
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

3.  CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.

Authors:  Alessio Biagioni; Anastasia Chillà; Mario Del Rosso; Gabriella Fibbi; Francesca Scavone; Elena Andreucci; Silvia Peppicelli; Francesca Bianchini; Lido Calorini; Anna Li Santi; Pia Ragno; Francesca Margheri; Anna Laurenzana
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

4.  uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines.

Authors:  Alessio Biagioni; Anna Laurenzana; Anastasia Chillà; Mario Del Rosso; Elena Andreucci; Martina Poteti; Daniele Bani; Daniele Guasti; Gabriella Fibbi; Francesca Margheri
Journal:  Cells       Date:  2020-01-28       Impact factor: 6.600

5.  uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells.

Authors:  Elena Andreucci; Anna Laurenzana; Silvia Peppicelli; Alessio Biagioni; Francesca Margheri; Jessica Ruzzolini; Francesca Bianchini; Gabriella Fibbi; Mario Del Rosso; Chiara Nediani; Simona Serrat; Livia Fucci; Michele Guida; Lido Calorini
Journal:  Oncol Res       Date:  2021-07-27       Impact factor: 5.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.